CD163 and melanoma: Doxorubicin-loaded stealth liposomes coated with an anti-CD163 monoclonal antibody [307] have shown promising results regarding tumor regression in mouse models of PD-1 therapy resistant melanomas [325] and metastatic ovarian cancer [326].